Identification of lncRNAs Indicating Immune Pathway Activity for Predicting Prognosis and Immunotherapy Response in Pan‐Cancer
Cancer Medicine · 2026
DOI: 10.1002/cam4.71827 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2026. Verfasst von Mengyu Xin und 11 weiteren Autor:innen. Beteiligte Einrichtung: College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China. Hauptthemen laut MEDLINE: RNA, Long Noncoding, Immunotherapy, Biomarkers, Tumor, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Heilongjiang Province.
Abstract (Originalsprache)
Background
The critical role of long non‐coding RNAs (lncRNAs) in tumor immunity has garnered increasing attention, and immune pathways are key regulatory factors in tumor immune mechanisms. However, current research on the association between lncRNAs and immune pathways remains limited. Therefore, quantifying this association may provide new insights for predicting prognosis and immunotherapy response.
Methods
A method was developed to classify candidate immune‐related lncRNAs into complex (CIlncRNAs), moderate (MIlncRNAs), and specific (SIlncRNAs) types based on the breadth of their associations with immune pathway activity. The features of these lncRNA types were then compared from multiple aspects.
Results
The genomic variations and correlations with DNA methylation of three types of immune‐related lncRNAs were significantly different in multiple cancers. CIlncRNAs were more strongly associated with immune infiltration than MIlncRNAs and SIlncRNAs. Lung adenocarcinoma (LUAD) patients were classified into two subtypes based on CIlncRNAs, with one subtype exhibiting better prognosis and higher immune cell infiltration. High expression of CIlncRNAs in immune cells and their role in CD8 + T cell differentiation in LUAD were validated using single‐cell data. Furthermore, a CIlncRNA signature (CIsig) was established for each cancer, and significant differences in overall survival (OS) were observed across risk stratifications in most cancers. Lastly, CIlncRNA was validated in independent datasets for its ability to predict immunotherapy response and enhance the predictive performance of established biomarkers.
Conclusions
Overall, our analysis innovatively explores the breadth of associations between lncRNAs and immune pathway activity. We identified CIlncRNAs as potential novel biomarkers for predicting patient prognosis and immunotherapy response, offering valuable insights for clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
- Department of Gynecology, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Heilongjiang Province
Zitieren
APA
Xin, M., He, D., Dai, Y., Liu, Q., Sun, R., Li, H., Zhang, Y., Li, J., Ning, S., Guo, Q., Gao, Y., & Wang, P. (2026). Identification of lncRNAs Indicating Immune Pathway Activity for Predicting Prognosis and Immunotherapy Response in Pan‐Cancer. Cancer Medicine. https://doi.org/10.1002/cam4.71827
Vancouver
Xin M, He D, Dai Y, Liu Q, Sun R, Li H, et al. Identification of lncRNAs Indicating Immune Pathway Activity for Predicting Prognosis and Immunotherapy Response in Pan‐Cancer. Cancer Medicine. 2026. doi:10.1002/cam4.71827
BibTeX
@article{Xin2026,
author = {Xin, Mengyu and He, Danni and Dai, Yifan and Liu, Qian and Sun, Rui and Li, Houxing and Zhang, Yujie and Li, Jiatong and Ning, Shangwei and Guo, Qiuyan and Gao, Yue and Wang, Peng},
title = {Identification of lncRNAs Indicating Immune Pathway Activity for Predicting Prognosis and Immunotherapy Response in Pan‐Cancer},
journal = {Cancer Medicine},
year = {2026},
doi = {10.1002/cam4.71827}
}
EUVIMED